华为加码医疗AI，医疗创新ETF(516820)持续获资金关注

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with stocks showing mixed results, led by Haikang and Dabo Medical, while Pianzaihuang experienced a decline [1] - The Medical Innovation ETF has seen continuous net inflows over the past 10 days, with a peak single-day net inflow of 41.83 million yuan, totaling 186 million yuan, averaging 18.58 million yuan daily [1] - Huawei Cloud is set to launch the first implementation area of its industry AI "Dream Factory" plan, focusing on smart healthcare, aiming to integrate top medical resources and cutting-edge technology [1] Group 2 - Guojin Securities notes that global pharmaceutical companies have effectively initiated AI platform construction, significantly enhancing efficiency in target discovery, molecular generation, and clinical trial design [2] - The Medical Innovation ETF closely tracks the China Securities Pharmaceutical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies from the pharmaceutical and medical device sectors [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, collectively accounting for 63.75% of the index [2]